Inhibition of trauma-associated inflammatory liver damage by blocking NF-κB activity

Hepato-Gastroenterology

Volumn 59, Issue 116, 2012, Pages 1174-1178

  Yang, Wenjun ^a   Zheng, Yihu ^a   He, Han ^a   Zhang, Huxiang ^a   Wan, Li ^a   Zhang, Qiyu ^a   Yu, Zhengping ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Decoy strategy; Inter leukin 6; Nuclear factor B; Traumatic inflammation; Tumor necrosis factor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; OLIGONUCLEOTIDE; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GEL MOBILITY SHIFT ASSAY; HISTOPATHOLOGY; LIVER INJURY; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE INJURY; TRANSMISSION ELECTRON MICROSCOPY;

ALANINE TRANSAMINASE; ANIMALS; INFLAMMATION; INTERLEUKIN-6; LIVER; LIVER DISEASES; NF-KAPPA B; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA; WOUNDS AND INJURIES;

EID: 84861371492     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11624     Document Type: Article

References (20)

1. Giannoudis PV: Current concepts of the inflammatory response after major trauma: an update. Injury 2003; 34:397-404.
2. Pallister I: Current concepts of the inflammatory response after major trauma: an update. Injury 2005; 36:227-9; author reply 9-30.
3. Harbrecht BG, Zenati MS, Doyle HR, et al.: Hepatic dysfunction increases length of stay and risk of death after injury. J Trauma 2002; 53:517-23.
4. Ghosh S, Karin M: Missing pieces in the NF-kappaB puzzle. Cell 2002; 109 Suppl:S81-96.
5. Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3:221-7.
6. Maeda S, Omata M: Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci 2008; 99:836-42.
7. Malato Y, Sander LE, Liedtke C, et al.: Hepatocyte-specific inhibitor-of-kappaB-kinase deletion triggers the innate immune response and promotes earlier cell proliferation during liver regeneration. Hepatology 2008; 47:2036-50.
8. Chen H, Yang S, Yang Z, Ma L, Jiang D, Mao J, et al.: Inhibition of GSK-3beta decreases NF-kappaB-dependent gene expression and impairs the rat liver regeneration. J Cell Biochem 2007; 102:1281-9.
9. Miyake T, Aoki M, Masaki H, Kawasaki T, Oishi M, Kataoka K, et al.: Regression of abdominal aortic aneurysms by simultaneous inhibition of nuclear factor kappaB and ets in a rabbit model. Circ Res 2007; 101:1175-84.
10. Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ: Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990; 250:997-1000.
11. Morishita R, Sugimoto T, Aoki M, et al.: In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997; 3:894-9.
12. Zhang N, Xu YJ, Zhang ZX, Xiong WN: In vivo transfection of cis element 'decoy' against nuclear factor-kappaB binding site modulates function of T lymphocytes in asthma. Zhonghua Jie He He Hu Xi Za Zhi 2004; 27:36-40.
13. Morishita R, Higaki J, Tomita N, Ogihara T: Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998; 82:1023-8.
14. Zaidi G, Supakar PC: Identification of a nuclear protein interacting with a novel site on rat androgen receptor promoter after transcription factor NFkB is displaced from adjacent site. Mol Biol Rep 2003; 30:121-5.
15. Isner JM: Oligonucleotide therapeutics--novel cardiovascular targets. Nat Med 1997; 3:834-5.
16. fichtner-feigl S, fuss IJ, Preiss JC, Strober W, Kitani A: Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest 2005; 115:3057-71.
17. Tomita N, Azuma H, Kaneda Y, Ogihara T, Morishita R: Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseases. Curr Drug Targets 2003; 4:339-46.
18. Tomita N, Morishita R, Tomita T, Ogihara T: Potential therapeutic applications of decoy oligonucleotides. Curr Opin Mol Ther 2002; 4:166-70.
19. Tomita N, Ogihara T, Morishita R: Therapeutic potential of decoy oligonucleotides strategy in cardiovascular diseases. Expert Rev Cardiovasc Ther 2003; 1:463-70.
20. Moran A, Thacker SA, Arikan AA, et al.: IL-6-Mediated Activation of Stat3alpha Prevents Trauma/Hemorrhagic Shock-Induced Liver Inflammation. PLoS One 2011; 6(6): e21449.